NR3C2 and cardiovascular disorder: Several large clinical trials indicate that MR antagonists effectively treat heart failure with reduced ejection fraction, a typical cardiovascular disease of the elderly (Zannad et al., 2010; Pitt, 2012; Pitt et al., 2014).